Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPL026 in Healthy Volunteers and Major Depressive Disorder
NCT04673383Phase 2Completed
- Sponsor
- Small Pharma
- Start
- Feb 2021
- Primary completion
- Oct 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SPL026 in major depressive disorder (MDD) (4 arms), sponsored by Small Pharma. Primary endpoints: Safety and tolerability in healthy volunteers at 3 months and Montgomery-Asberg Depression Rating Scale at 2 weeks. Started Feb 2021; status: completed.
02
Drugs
SPL026
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04673383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04673383.